glucosamine linked – A new University of Florida study finds glucosamine use is associated with a 25% higher chance of developing dementia in people with mild cognitive impairment and a 25% higher risk of death among those already diagnosed with Alzheimer’s disease and related dem
On the same day a popular over-the-counter supplement is getting fresh scrutiny, a University of Florida research team published findings that could trouble millions of older adults who take glucosamine for joint pain.
In a study published June 9 in Nature Metabolism. people already showing signs of mild cognitive impairment were 25 percent more likely to develop dementia if they were taking glucosamine in supplement form than if they were not. Among patients who had already been diagnosed with Alzheimer’s disease and related dementias. glucosamine use was associated with a 25 percent increase in the risk of death.
The results land at a painful crossroads: Alzheimer’s disease and other dementias already shorten lives, and for many families, every new factor that might hasten decline can feel like an additional burden.
The research points to a possible mechanism tied to metabolism. Glucosamine, the study suggests, may interact with metabolic processes in the brain that are already disrupted in Alzheimer’s patients. Researchers also found a difference between the two groups: the increased mortality risk was only observed in patients with a dementia diagnosis. not in those with mild cognitive impairment.
That distinction matters. It suggests the impact, if it holds up in stronger testing, could depend on where a person is in the disease process.
Dr. Jessica McCarthy, a New Jersey-based neuropsychologist specializing in dementia assessment and neurodegenerative disorders, said the work builds on a broader view of Alzheimer’s.
“The study continues to build evidence towards the hypothesis that Alzheimer’s disease is not just a function of increased presence of amyloid plaques and tau proteins. but rather. it’s a combination of the aforementioned factors. along with metabolic dysfunction and inflammation. ” McCarthy said. “Because glucosamine crosses the blood brain barrier. it may worsen an already overactive metabolic pathway. facilitating a heightened risk of disease progression in people with mild cognitive impairment and mortality in people already diagnosed with Alzheimer’s.”.
McCarthy also warned against treating supplements like harmless shortcuts. “I’m not saying that supplements as a whole are problematic but taking supplements without understanding how they may interact with organ systems. pre-existing conditions. as well as other medications. can lead to problems. as this most recent study is suggesting. ” she said.
Glucosamine is one of the most widely used dietary supplements in the U.S. sold over the counter and marketed primarily for joint pain and cartilage support as people age. Because it is used frequently by older adults—the same population most at risk for Alzheimer’s—the University of Florida team set out to examine whether the supplement could be influencing the course of neurological decline and its increase in recent years.
The researchers used artificial intelligence to analyze anonymized patient health records from UF Health, collected between 2012 and 2024. They focused on two groups: patients diagnosed with Alzheimer’s disease and related dementias. and those with mild cognitive impairment. a condition that can sometimes be a precursor to Alzheimer’s.
In total. they identified 1. 896 patients with dementia and 2. 750 with mild cognitive impairment who reported taking glucosamine—approximately 8 percent of each group. After adjusting for variables including age. sex. and demographics. the data showed the pattern the study highlights: higher odds of progressing to dementia among glucosamine users with mild cognitive impairment.
To dig for biological explanations, researchers also conducted advanced imaging studies of human brain tissue and used mouse models of Alzheimer’s disease to look for mechanisms that might explain the association.
There’s a limit to what the study can prove, though. The researchers acknowledge that the findings are observational, and they say clinical trials will be needed to confirm the link. Still, McCarthy said she sees value in the direction the evidence is moving.
“From a behavior modification and a modifiable risk factor to dementia standpoint, the research is robust on how we can improve both brain health and metabolic health,” she said.
She pointed to steps she considers more firmly supported by evidence. including exercising with moderate intensity at least three or four times a week for at least 45 minutes at a time. with a focus on building muscle mass; getting adequate sleep and prioritizing sleep hygiene; implementing a Mediterranean diet; and taking prescribed medications.
If someone is already using supplements. McCarthy said the safest approach is to coordinate with clinicians rather than making changes alone. “If you are interested in supplements. it’s not something you should be doing independent of speaking with your medical team. ” she said. “We also know that a healthy and active brain is one that is stimulated. engaged intellectually and socially. fed well. and provided adequate time to rest.”.
By the end of the study’s findings. the takeaway is clear even as the science remains incomplete: glucosamine is widely sold. widely used. and—based on this analysis—linked to outcomes that families already fear. Whether that association reflects causation is the question for future trials. For now. the study adds more urgency to the conversation about who should take what. and how doctors and patients decide together.
In a disease where time matters, even a 25 percent shift in risk can feel like a warning—one that comes with a call for caution, careful coordination, and follow-up research that goes beyond what observational data can establish.
glucosamine Alzheimer’s disease mild cognitive impairment dementia Nature Metabolism University of Florida UF Health dementia risk supplement safety